Liraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
Open accessAbstract
AIMS: This article reviews practical issues that healthcare providers need to consider when implementing therapy with the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide. KEY POINTS: Liraglutide is administered once daily by subcutaneous injection, independent of meals and at any time of day. To improve gastro-intestinal tolerability, the starting dose is 0.6 mg liraglutide daily. After at least 1 week, the dose should be increased to 1.2 mg. Some patients may benefit from an additional increment to the maximum recommended daily dose of 1.8 mg. Daily blood glucose monitoring is not required, although may be necessary if liraglutide is used with a sulphonylurea (SU). Treatment is contraindicated in patients with known hypersensitivity to liraglutide or an excipient. Liraglutide slows gastric emptying, but does not interact with acetaminophen, oral contraceptives, atorvastatin, griseofulvin, lisinopril or digoxin in a way that necessitates dose adjustments of these agents. The efficacy and safety of liraglutide are not influenced by differences in gender, age or ethnicity and race. Overall, liraglutide is generally well tolerated. Patients can experience gastrointestinal side effects, such as nausea, which diminish over time. As liraglutide increases insulin production in a glucose-dependent manner, the incidence of hypoglycaemia largely depends on the hypoglycaemic risk profile of the selected oral antidiabetic with which it is used. The use of an SU may increase the risk of hypoglycaemia; this risk can be lowered by reducing the SU dose. CONCLUSIONS: Liraglutide is a once-daily treatment option that can be used in adults with type 2 diabetes regardless of gender, age (although therapeutic experience in patients over 75 years of age is limited) and ethnicity or race.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The size of the effect on gastric emptying is not of a magnitude that necessitates dose adjustments of concomitantly administered oral medications.
“The size of the effect on gastric emptying is not of a magnitude that necessitates dose adjustments of concomitantly administered oral medications.14”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [14]
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923 · see citing works
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · see citing works
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · see citing works
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · see citing works
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472 · see citing works
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · see citing works
Vascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · see citing works
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · see citing works
Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165722 · Cited by 69 · see citing works
Ard, J., Cannon, A., Lewis, C. E., Lofton, H., Vang Skjøth, T., Stevenin, B., & Pi‐Sunyer, X. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12632 · Cited by 43 · see citing works
- Authors
- Peterson, G. E., & Pollom, R. D.
- Affiliations
- Des Moines University (US)
- Community Health Network (US)
- Corresponding author
- Peterson, G. E.
- ORCID
- Pollom, R. D.
- Venue
- International Journal of Clinical Practice
- Publisher
- Wiley
- Published
- 2010-09-23
- Volume
- 64
- Issue
- 167
- Pages
- 35-43
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W1488049042
- Cited by
- 55
- References
- 11
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 1 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 3
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- International Journal of Clinical Practice (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor agonists, type 2 diabetes, dosage, subcutaneous administration, gastrointestinal tolerance, nausea, hypoglycemia, drug interactions, drug safety, efficacy, older adults
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Contraindications, Adult, Diabetes Mellitus, Type 2, Drug Interactions, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Nausea, Sulfonylurea Compounds, Treatment Outcome, Receptors, Glucagon, Glucagon-Like Peptide 1, Drug Dosage Calculations, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
